POMALIDOMID - nowy immunomodulujÄ cy lek w terapii szpiczaka plazmocytowego

Multiple myeloma (MM) is a haematological disease characterized by plasma cells proliferation in bone marrow associated with damage of organs - mainly kidneys and bones. Previous therapies significantly extended the survival of patients, but still relapse is 100%. In February 2013, in USA, the Food and Drug Administration (FDA) introduced to therapy a new immunomodulatory drug - pomalidomide. In European Union this drug under the name IMNOVID was registered in August 2013. The authors review the mechanisms of action, pharmacokinetic and clinical properties of pomalidomide. The data discussed in this article come from publications on clinical trials I, II and III phase. It seems this drug may be a breakthrough in the treatment of MM.